Health Canada released a Dear Health Professional Letter on December 15, 2020 to advise healthcare professionals, including urologists, urogynecologists, ophthalmologists, optometrists, family physicians, and pharmacists about cases of pigmentary maculopathy reported with use of Elmiron.
As discussed in our previous post Elmiron is a medication prescribed to treat interstitial cystitis and has been linked to vision loss.
Cases of pigmentary maculopathy, which involves changes to the retina that can cause vision loss and impairment, have been reported with Elmiron usage. Individuals who have used Elmiron for three years or longer are particularly at risk.
The Health Canada publication advises healthcare professionals of the risk of pigmentary maculopathy with Elmiron and contraindicates the drug in patients with a history of macular disease.
The Canadian Product Monograph for Elmiron has been updated to include the contraindication and to provide information about the risk of pigmentary maculopathy.
Siskinds LLP has commenced class proceedings on behalf of Canadians that have suffered vision impairment related to the usage of Elmiron. Siskinds LLP is available and willing to review and discuss your potential case. If you or a loved one has suffered vision impairment or injury following usage of Elmiron, please contact our medical product liability team for the class action here.
Originally Published by Siskinds, December 2020
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
